

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Suda Pharmaceuticals Ltd
ABN	35 090 987 250

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Paul Hopper
Date of last notice	6 January 2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Director and shareholder of Moreglade Pty Ltd <The Hopper Super Fund A/c>
Date of change	5 August 2020
No. of securities held prior to change	Held indirectly i. 280,000 Ordinary Shares ii. 520,000 Unlisted Options (14/5/2022; 14.75 cents) iii. 520,000 Unlisted Options (14/5/2022; 15.75 cents) iv. 560,000 Unlisted Options (14/5/2022; 16.75 cents)
Class	Ordinary Shares with attaching listed options
Number acquired	280,000 Ordinary Shares 93,334 Listed Options (SUDOE)

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

Number disposed	nil
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$7,000
No. of securities held after change	Held indirectly i. 560,000 Ordinary Shares ii. 520,000 Unlisted Options (14/5/2022; 14.75 cents) v. 520,000 Unlisted Options (14/5/2022; 15.75 cents) vi. 560,000 Unlisted Options (14/5/2022; 16.75 cents) vii. 93,334 Listed Options (SUDOE) (31/7/2022; 5 cents)
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issue of shares and attaching options under the entitlement offer announced on 3 July 2020.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

+ See chapter 19 for defined terms.

For personal use only

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	Yes – as the acquisition was made during an Entitlement Offer.
If so, was prior written clearance provided to allow the trade to proceed during this period?	Yes
If prior written clearance was provided, on what date was this provided?	2 July 2020

Dated 7 August 2020



Joseph Ohayon
Joint Company Secretary

+ See chapter 19 for defined terms.

For personal use only